The Role of TP53, KRAS, CDH1, Demographic and Clinical Variables in Gastric Cancer

Overview

Journal Mater Sociomed

Date 2025 Feb 18

PMID 39963439

Authors

Ali Abu Siyam

Suha Khayri Ababneh

Ibrahim Al-Odat

Sokiyna Ababneh

Ahed J Alkhatib

Affiliations

Soon will be listed here.

Abstract

Background: Worldwide, gastric cancer remains the fifth most prevalent type of cancer and is the third leading cause of cancer-related deaths. Gastric cancer is responsible for around 7% of global cancer occurrence and approximately 9% of annual cancer-related mortalities.

Objective: The aim of the study was to analyze gastric cancer dataset posted on Kaggle (https://www.kaggle.com/datasets/datasetengineer/gastric-cancer-gc-dataset).

Methods: This dataset comprises 212354 participants, of whom 10% had gastric cancer. This dataset was analyzed to extract the information regarding gastric cancer. The analysis of data was performed SPSS version 25. Descriptive analysis was used to describe data including frequency and percentages to describe categorical variables such as age, and the mean and standard deviation to describe non-categorical variables such as age. The relationships between variables and gastric cancer were calculated based on Chi-Square and One Way ANOVA tests, significance was considered if p value ≤0,05.

Results: The mean age was 53.2580±18.98 years. Seventy percent of participants were males. About 30% of participants had a family history of gastric cancer. About 40% of participants were smokers. About 50% of participants were alcoholic. About 75% of participants had Helicobacter pylori. 80% of participants were at high salt intake. About 50% of participants had chronic gastritis. Abnormal endoscopic image reports were reported in approximately 30% of participants. Biopsy results were negative in 90% of participants. The reports of CT scans were negative in approximately 80%. Genetic mutations were detected in Tp53 (50.1%), KRAS (20%), and CDH1 (29,9%). No significant relationships were found between gastric cancer and study variables.

Conclusion: Most of the people had risk factors such as Helicobacter pylori infection, salt intake, and mutations in TP53, KRAS, and CDH1. However, statistical analyses did not find significant correlations between those and gastric cancer.

References

Thrift A, Wenker T, El-Serag H . Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023; 20(5):338-349. DOI: 10.1038/s41571-023-00747-0. View

Nie Z, Zeng K, Yan Q, Liu Y, Bian Y, Zhu J . The Relationship Between Gene Mutations and the Clinicopathological Features and Prognosis of Gastric Cancer. Int J Surg Pathol. 2023; 32(3):486-495. DOI: 10.1177/10668969231188421. View

Yang W, Zhao H, Yu Y, Wang J, Guo L, Liu J . Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol. 2023; 29(16):2452-2468. PMC: 10167900. DOI: 10.3748/wjg.v29.i16.2452. View

Bellini M, Cadamuro A, Succi M, Proenca M, Silva A . Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol. 2012; 2012:891961. PMC: 3420349. DOI: 10.1155/2012/891961. View

Zhang Q, Sun X, Sun J, Lu J, Gao X, Shen K . RNA mC regulator-mediated modification patterns and the cross-talk between tumor microenvironment infiltration in gastric cancer. Front Immunol. 2022; 13:905057. PMC: 9646743. DOI: 10.3389/fimmu.2022.905057. View

Nussinov R, Tsai C, Jang H . A New View of Activating Mutations in Cancer. Cancer Res. 2022; 82(22):4114-4123. PMC: 9664134. DOI: 10.1158/0008-5472.CAN-22-2125. View

Zhang R, Li H, Li N, Shi J, Li J, Chen H . Risk factors for gastric cancer: a large-scale, population-based case-control study. Chin Med J (Engl). 2021; 134(16):1952-1958. PMC: 8382323. DOI: 10.1097/CM9.0000000000001652. View

Karimi P, Islami F, Anandasabapathy S, Freedman N, Kamangar F . Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014; 23(5):700-13. PMC: 4019373. DOI: 10.1158/1055-9965.EPI-13-1057. View

Ko K . Risk Factors of Gastric Cancer and Lifestyle Modification for Prevention. J Gastric Cancer. 2024; 24(1):99-107. PMC: 10774756. DOI: 10.5230/jgc.2024.24.e10. View

10.

Maddineni G, Xie J, Brahmbhatt B, Mutha P . Diet and carcinogenesis of gastric cancer. Curr Opin Gastroenterol. 2022; 38(6):588-591. DOI: 10.1097/MOG.0000000000000875. View

11.

Zhu C, Guan X, Zhang X, Luan X, Song Z, Cheng X . Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022; 21(1):159. PMC: 9351107. DOI: 10.1186/s12943-022-01629-2. View

12.

Hu S, Zhao X, Qian F, Jin C, Hou K . Correlation between Mutations and Tumor Mutation Burden in Gastric Cancer. Comput Math Methods Med. 2021; 2021:1522250. PMC: 8481040. DOI: 10.1155/2021/1522250. View

13.

Kennedy M, Lowe S . Mutant p53: it's not all one and the same. Cell Death Differ. 2022; 29(5):983-987. PMC: 9090915. DOI: 10.1038/s41418-022-00989-y. View

14.

Song Y, Liu X, Cheng W, Li H, Zhang D . The global, regional and national burden of stomach cancer and its attributable risk factors from 1990 to 2019. Sci Rep. 2022; 12(1):11542. PMC: 9262989. DOI: 10.1038/s41598-022-15839-7. View

15.

Li J, Kuang X, Zhang Y, Hu D, Liu K . Global burden of gastric cancer in adolescents and young adults: estimates from GLOBOCAN 2020. Public Health. 2022; 210:58-64. DOI: 10.1016/j.puhe.2022.06.010. View

16.

Levine A . Spontaneous and inherited TP53 genetic alterations. Oncogene. 2021; 40(41):5975-5983. PMC: 8516647. DOI: 10.1038/s41388-021-01991-3. View

17.

Scherubl H . Tobacco Smoking and Gastrointestinal Cancer Risk. Visc Med. 2022; 38(3):217-222. PMC: 9209969. DOI: 10.1159/000523668. View

18.

Jang H, Lee A, Kang J, Song I, Lee S . Prediction of genetic alterations from gastric cancer histopathology images using a fully automated deep learning approach. World J Gastroenterol. 2021; 27(44):7687-7704. PMC: 8641056. DOI: 10.3748/wjg.v27.i44.7687. View

19.

Judd J, Karim N, Khan H, Naqash A, Baca Y, Xiu J . Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Mol Cancer Ther. 2021; 20(12):2577-2584. PMC: 9662933. DOI: 10.1158/1535-7163.MCT-21-0201. View

20.

Wei C, Li M, Lin S, Xiao J . Characterization of Tumor Mutation Burden-Based Gene Signature and Molecular Subtypes to Assist Precision Treatment in Gastric Cancer. Biomed Res Int. 2022; 2022:4006507. PMC: 9122698. DOI: 10.1155/2022/4006507. View